-
Mashup Score: 2
Despite FDA approval of sipuleucel-T in 2010, endeavors to use immune checkpoint inhibitors in unselected prostate cancer patients have not improved clinical outcomes. These efforts include studies…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 50
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care - 1 month(s) ago
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care - 1 month(s) ago
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 54Biochemically recurrent prostate cancer in the era of... : Current Opinion in Oncology - 1 month(s) ago
egies and emerging therapeutic data. Managing BCR requires a unique perspective in oncology that balances toxicities and disease kinetics. Recent findings Prostate specific membrane antigen (PSMA) imaging is now widely available and can define subclinical disease in patients with BCR who otherwise have negative CT and bone scans, but limited data exists showing that treating PSMA-positive disease has long term impact. A phase 3 trial demonstrated that the androgen receptor pathway inhibitor enzalutamide either alone or with androgen deprivation therapy (ADT) was superior in delaying metastasis, relative to ADT alone. Survival benefits from this study remain unknown. Summary BCR is a heterogeneous population where overtreatment may present greater risk to patients than a disease course that is often indolent. Management of BCR should be individualized based on disease kinetics. Given the unique biology of BCR, future therapeutic research should emphasize an approach that alters disease
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer. - 2 month(s) ago
Abstract. Therapies that abrogate persistent androgen receptor (AR) signaling in castration resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain (NTD) of the AR that drives transcriptional activity in CRPC remains a challenging therapeutic target. Herein we demonstrate that BAG-1 mRNA is highly expressed and associates with signaling pathways, including AR signaling, that are implicated in the development and progression of CRPC. In addition, interrogation of geometric and physiochemical properties of the BAG domain of BAG-1 isoforms identifies it to be a tractable but challenging drug target. Furthermore, through BAG-1 isoform mouse knockout studies we confirm that BAG-1 isoforms regulate hormone physiology and that therapies targeting the BAG domain will be associated with limited ‘on-target’ toxicity. Importantly, the postulated inhibitor of BAG-1 isoforms, Thio-2, suppressed AR signaling and other important pathways implicated in the development and
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
CCR’s Physician-Scientist Early Investigator Program (PEIP) is a highly competitive opportunity intended for physicians dedicated to laboratory bench-to-bedside or clinic-based research. This position is in a mentored three-to-five-year independent research program and is equivalent to a starting faculty position in academia.
Source: ccr.cancer.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer - 3 month(s) ago
w/out clinical context #PSMA PET imaging may lead to substantial over treatment in pts w/recurrent #ProstateCancer
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
Purpose A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was performed to evaluate the addition of bevacizumab to standard docetaxel and prednisone therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods Patients with chemotherapy-naive progressive mCRPC with Eastern Cooperative Oncology Group performance status ≤ 2 and adequate bone marrow, hepatic, and renal function were randomly assigned to receive docetaxel 75 mg/m2 intravenously (IV) over 1 hour for 21 days plus prednisone 5 mg orally twice per day (DP) with either bevacizumab 15 mg/kg IV every 3 weeks (DP + B) or placebo. The primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), 50% decline in prostate-specific antigen, objective response (OR), and toxicity. Results In total, 1,050 patients were randomly assigned
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
@RPachynski @SitemanCenter @WashUOnc @PCF_Science @PamSharmaMDPhD @JimAllisonPhD @gulleyj1 Agree-I think #cytokines may lead us down a new path of discovery in #ProstateCancer #Immunotherapy Glad to see this work from you & your team We have several studies w/cytokines in prostate cancer ongoing & opening @theNCI https://t.co/gyKGP6xG4C